The ZETA Trial, a Phase III study, showed that patients with medullary thyroid cancer (MTC) who had a somatic RET M918T mutation had a higher objective response rate to vandetanib (55%) than patients with sporadic MTC tumors that lacked a somatic M918T mutation (33%) [11]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.